Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$6,759 Mln
Revenue (TTM)
$4,427 Mln
Net Profit (TTM)
$0 Mln
ROE
0.1 %
ROCE
-- %
P/E Ratio
18.3
P/B Ratio
1
Industry P/E
28.33
EV/EBITDA
7.5
Div. Yield
0 %
Debt to Equity
0.7
Book Value
$--
EPS
$0.7
Face value
--
Shares outstanding
496,646,016
CFO
$2,212.70 Mln
EBITDA
$6,210.30 Mln
Net Profit
$-2,752.10 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Elanco Animal Health (ELAN)
| 10.1 | 3.2 | 25.3 | -26.9 | -13.4 | -9.2 | -- |
|
BSE Sensex*
| 4.0 | -1.2 | 8.0 | 5.3 | 16.6 | 18.9 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Elanco Animal Health (ELAN)
| -18.6 | 21.9 | -56.9 | -7.5 | 4.1 | -6.6 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Elanco Animal Health (ELAN)
|
13.3 | 6,759.4 | 4,427.0 | 373.0 | -0.7 | 5.8 | 18.3 | 1.0 |
| 18.1 | 4,328.3 | 459.4 | 206.8 | 25.6 | 68.3 | 21.6 | 13.3 | |
| 7.9 | 3,677.7 | 2,830.2 | -13.1 | 11.5 | -- | -- | 86.1 | |
| 29.3 | 3,533.7 | 8.9 | -369.2 | -4,861.1 | -26.1 | -- | 2.7 | |
| 102.9 | 5,065.9 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 95.2 | |
| 55.2 | 10,593.7 | 2,937.8 | 523.9 | 23.2 | 9.3 | 20.4 | 1.9 | |
| 40.0 | 7,608.5 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 71.2 | 7,619.3 | 685.5 | 132.9 | 15.6 | 20.1 | 61.9 | 11.0 | |
| 83.6 | 4,135.0 | 1,137.8 | 214.6 | 29.2 | 12.3 | 19.5 | 2.3 | |
| 8.8 | 10,293.2 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.7 |
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect... pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana. Address: 2500 Innovation Way, Greenfield, IN, United States, 46140 Read more
President, CEO & Director
Mr. Jeffrey N. Simmons
President, CEO & Director
Mr. Jeffrey N. Simmons
Headquarters
Greenfield, IN
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Elanco Animal Health (ELAN) stood at $ 14,210 Mln as on 31-Mar-25
The share price of Elanco Animal Health (ELAN) is $13.33 (NYSE) as of 18-Jun-2025 16:02 EDT. Elanco Animal Health (ELAN) has given a return of -13.44% in the last 3 years.
Elanco Animal Health (ELAN) has a market capitalisation of $ 6,759 Mln as on 18-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Elanco Animal Health (ELAN) is 1.04 times as on 18-Jun-2025, a 78% discount to its peers’ median range of 4.82 times.
The P/E ratio of Elanco Animal Health (ELAN) is 18.26 times as on 18-Jun-2025, a 36% discount to its peers’ median range of 28.33 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Elanco Animal Health (ELAN) and enter the required number of quantities and click on buy to purchase the shares of Elanco Animal Health (ELAN).
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana. Address: 2500 Innovation Way, Greenfield, IN, United States, 46140
The CEO & director of Mr. Jeffrey N. Simmons. is Elanco Animal Health (ELAN), and CFO & Sr. VP is Mr. Jeffrey N. Simmons.
There is no promoter pledging in Elanco Animal Health (ELAN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,096
|
|
|
1,054
|
|
|
755
|
|
|
741
|
|
|
532
|
|
|
522
|
|
|
421
|
|
|
386
|
|
|
362
|
| Elanco Animal Health (ELAN) | Ratios |
|---|---|
|
Return on equity(%)
|
5.79
|
|
Operating margin(%)
|
-0.7
|
|
Net Margin(%)
|
8.43
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Elanco Animal Health (ELAN) was $0 Mln.
$-0.28
(
